TAKNYSEPharmaceutical PreparationsAlso trades as TKPHF
TAKEDA PHARMACEUTICAL CO LTD
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 17, 2026
$19.61−0.06 (-0.31%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2016 to 2026
Gross margin
65.1%−3.8 pts over 5 years
Operating margin
0.1%−15.8 pts over 5 years
Net margin
-3.4%−15.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -1.7% | +3.8% | +7.1% | – | |
| Gross profit | -2.2% | +1.8% | +5.9% | – | |
| Operating income | -98.2% | -76.7% | -58.6% | – | |
| Free cash flow | +1.1% | +1.1% | -0.8% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | 7.6% | -2.1% | |
| Return on assets | – | 2.9% | -1.0% | |
| Current ratio | – | 1.53 | 1.09 | |
| Debt to equity | – | 0.90 | 0.66 | |
| Net debt to EBITDA | – | 3.43× | 5.89× | |
| Interest coverage | 6.7× | 2.0× | 0.0× | |
| Inventory turnover | – | 1.3× | 1.2× | |
| Capex to revenue | 3.6% | 3.5% | 3.9% | |
| Diluted shares | 786M | 1.57B | 1.58B |
Where the cash went
Fiscal 2022 to 2026, five years combined
Takeda Pharmaceutical generated ¥4.92T from operations and spent ¥2.49T on capital expenditure, dividends and share buybacks. 33% of that went back into the business.
Generated
¥4.92T
Used
¥2.49T
Capital expenditure¥816.13B33%Dividends¥1.46T59%Share buybacks¥210.25B8%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-3.4%
×Asset turnover0.30×
×Equity multiplier2.07×
=Return on equity, FY2026-2.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -3.4% | 0.30× | 2.07× | -2.1% |
| FY2025 | 2.4% | 0.31× | 2.07× | 1.5% |
| FY2024 | 3.4% | 0.29× | 2.13× | 2.1% |
| FY2023 | 7.9% | 0.30× | 2.25× | 5.3% |
| FY2022 | 6.4% | 0.27× | 2.40× | 4.2% |
| FY2021 | 11.8% | 0.25× | 2.60× | 7.6% |
| FY2020 | 1.3% | 0.25× | 2.69× | 0.9% |
| FY2019 | 6.4% | 0.23× | 2.49× | 3.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
5of 9 tests passed in fiscal 2026. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-¥152.39B
- Cash generatingOperating cash flow above zero¥1.04T
- Return on assets improvedROA up on the prior year0.7% → -1.1%
- Earnings backed by cashOperating cash flow above net income¥1.04T vs -¥152.39B
- Less leverageLong-term debt to assets fell27.8% → 28.2%
- Better liquidityCurrent ratio rose1.01 → 1.09
- No dilutionShare count did not rise1.61B → 1.58B
- Gross margin improvedGross margin up on the prior year65.51% → 65.12%
- More efficientAsset turnover rose0.30 → 0.32